ClinicalTrials.gg
TerminatedNCT03370120Updated Dec 29, 2021Results posted

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

A Phase 2 interventional study of Padsevonil in Drug-Resistant Epilepsy and Focal-Onset Seizures, sponsored by UCB Biopharma SRL. Terminated at 156 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
406
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Enrollment
5th of 67
406 · median 27
Started
2018
with 4 others
Phase 2
9 of 78
1 open now
Registered
17th of 78
by date
Lead sponsor
2 of 78
UCB Biopharma SRL

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 5th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 9 in phase 2, and was the 17th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 40 (60%) stop at 75 or younger; 26 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.

03

Conditions studied

  • Drug-Resistant Epilepsy
  • Focal-Onset Seizures

Keywords

  • Drug-Resistant Epilepsy
  • Padsevonil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an adult (18 years of age or more )
  • Subject with epilepsy who has completed 1 of the previous Padsevonil (PSL) studies which allow access to the present study
  • Female subjects of child bearing potential must have a serum negative pregnancy test at the Entry Visit, which is confirmed to be negative by urine testing prior to further dispensing at each study visit thereafter. Subjects will be withdrawn from the study as soon as pregnancy is known. Female subjects will use an efficient form of for the duration of the study and for a period of 3 months after their final dose of PSL.

Exclusion criteria

Exclusion Criteria:

  • Subject has any severe medical, neurological, or psychiatric condition, or laboratory value which may have an impact on the safety of the subject
  • Subject has active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Subject has >2x (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total (>= l.5x ULN total bilirubin if known Gilbert's syndrome) at the Entry Visit
  • Subject has a clinically-significant abnormality on (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Subject has an abnormality on echocardiogram at last echocardiogram assessment, or foreseen in parent study as assessed by central reader that is accompanied by clinical symptoms or a Grade 2* (or higher)/moderate severity abnormality, or a history of rheumatic heart disease, or other known valvular abnormalities (*according to the ASE Guidelines, 2017; Zoghbi et al 2017)
  • Female subject who plans to be pregnant or is breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Padsevonil

    Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study. Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available.

    Drug: Padsevonil

Interventions

  • * Pharmaceutical Form: film-coated tablet * Route of Administration: Oral use

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study

    An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.

    Time frame: From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)

  2. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal

    An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.

    Time frame: From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)

  3. Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period

    Seizure frequency refers to 28-day adjusted frequency. Observable focal-onset seizures refer to Type IAl, IB, and IC (according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981). Focal-onset seizures include all Type I seizures.

    Time frame: From Baseline in respective parent study over the Evaluation Period (up to approximately 2 years) in this study

07

Results

Posted Dec 29, 2021

Participant flow

The study started to enroll study participants in August 2018 and concluded in December 2020.

Participant flow — Overall Study
MilestonePadsevonil
Started406
Completed0
Not completed406
Withdrew: Adverse event, non-fatal24
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up1
Withdrew: Lack of efficacy37
Withdrew: Per sponsor's instructions1
Withdrew: Study was terminated by parent company ucb2
Withdrew: The study was ended by the promoter3
Withdrew: Discontinuation of drug development3
Withdrew: End of project2
Withdrew: Premature study closure2
Withdrew: Premature program termination1
Withdrew: Premature study termination7
Withdrew: Trial terminated by sponsor2
Withdrew: Trial discontinued by sponsor2
Withdrew: Study ended15
Withdrew: Clinical trial has been cancelled1
Withdrew: End of study per sponsor decision2
Withdrew: Promoter's decision2
Withdrew: The trial has been suspended3
Withdrew: Sponsor stopped psl development based on data3
Withdrew: Early termination by order of sponsor2
Withdrew: Discontinuation of the study5
Withdrew: End of clinical trial discontinuation1
Withdrew: Because the clinical trial ended halfway4
Withdrew: Development discontinued5
Withdrew: Padsenovil program closed3
Withdrew: End of project2
Withdrew: Termination of project1
Withdrew: The study was interrupted by sponsor4
Withdrew: The protocol was interrupted by sponsor1
Withdrew: End of sponsor decision1
Withdrew: The study was terminated prematurely by study lead1
Withdrew: Early termination of studies5
Withdrew: This study is ended early1
Withdrew: End of padsevonil program2
Withdrew: Decision of sponsor6
Withdrew: Asked by the sponsor3
Withdrew: Sponsor decision to stop the protocol1
Withdrew: Pi decision poor compliance from participant1
Withdrew: Promoter ended the study3
Withdrew: Premature study close by sponsor's decision4
Withdrew: Study terminated by sponsor33
Withdrew: Sponsor prematurely terminated this study2
Withdrew: Sponsor decision to terminate study63
Withdrew: Program closure3
Withdrew: Study ended prematurely1
Withdrew: Study stopped by sponsor2
Withdrew: Program termination55
Withdrew: Sponsor decision62
Withdrew: Sponsor study closure10

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study

An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.

Time frame:
From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study
percentage of participantsPadsevonil (SS)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study72.2
PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal

An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.

Time frame:
From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal
percentage of participantsPadsevonil (SS)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal5.2
PrimaryChange From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period

Seizure frequency refers to 28-day adjusted frequency. Observable focal-onset seizures refer to Type IAl, IB, and IC (according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981). Focal-onset seizures include all Type I seizures.

Time frame:
From Baseline in respective parent study over the Evaluation Period (up to approximately 2 years) in this study
Reported as:
Mean · seizures per 28 days
Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period
seizures per 28 daysPadsevonil (FAS)
Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period-7.73 ± 27.52

Adverse events

Collected over From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Padsevonil (SS)0/406 (0%)48/406 (11.8%)184/406 (45.3%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPadsevonil (SS)
EpilepsyNervous system disorders7/406
Generalised tonic-clonic seizureNervous system disorders5/406
Status epilepticusNervous system disorders5/406
SeizureNervous system disorders4/406
Focal dyscognitive seizuresNervous system disorders2/406
Partial seizures with secondary generalisationNervous system disorders2/406
Seizure clusterNervous system disorders2/406
Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders2/406
Inappropriate antidiuretic hormone secretionEndocrine disorders1/406
Abdominal discomfortGastrointestinal disorders1/406
Most frequent other events
Most frequent other events
EventPadsevonil (SS)
SomnolenceNervous system disorders66/406
HeadacheNervous system disorders59/406
FatigueGeneral disorders47/406
DizzinessNervous system disorders43/406
NasopharyngitisInfections and infestations29/406
InsomniaPsychiatric disorders23/406
Memory impairmentNervous system disorders21/406

Baseline characteristics

The Safety Set (SS) consisted of all enrolled participants who were administered at least 1 dose of PSL, based on the first dose date from the first administration of study medication Case Report form (CRF).

Age, Categorical
Age, Categorical(Participants)Padsevonil
<=18 years0
Between 18 and 65 years395
>=65 years11
Age, Continuous
Age, Continuous(years)Padsevonil
Mean40.8 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Padsevonil
Female231
Male175
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Padsevonil
American Indian / Alaskan native5
Asian38
Black6
Native Hawaiian or other Pacific Islander5
White343
Other/mixed9
08

Study locations

156 sites
  • Ep0093 839
    Chandler, Arizona 85226, United States
  • Ep0093 815
    La Jolla, California 92037, United States
  • Ep0093 801
    San Francisco, California 94115, United States
  • Ep0093 803
    Honolulu, Hawaii 96817, United States
  • Ep0093 638
    Fort Wayne, Indiana 46804, United States
  • Ep0093 707
    Lexington, Kentucky 40536, United States
  • Ep0093 822
    Baltimore, Maryland 21287, United States
  • Ep0093 818
    Bethesda, Maryland 20817, United States
  • Ep0093 889
    Boston, Massachusetts 02215, United States
  • Ep0093 645
    Golden Valley, Minnesota 55422, United States
  • Ep0093 817
    Saint Paul, Minnesota 55102, United States
  • Ep0093 806
    Hackensack, New Jersey 07601, United States
  • Ep0093 895
    Bronx, New York 10467-24 01, United States
  • Ep0093 893
    Syracuse, New York 13210, United States
  • Ep0093 890
    Chapel Hill, North Carolina 27514, United States
  • Ep0093 884
    Charlotte, North Carolina 28204, United States
  • Ep0093 642
    Columbia, Ohio 43210, United States
  • Ep0093 802
    Philadelphia, Pennsylvania 19107, United States
  • Ep0093 838
    Cordova, Tennessee 38018, United States
  • Ep0093 835
    Nashville, Tennessee 37232, United States
  • Ep0093 805
    Austin, Texas 78701, United States
  • Ep0093 844
    Austin, Texas 78758, United States
  • Ep0093 824
    Round Rock, Texas 78681, United States
  • Ep0093 870
    San Antonio, Texas 78229, United States
  • Ep0093 639
    Renton, Washington 98055, United States
  • Ep0093 855
    Box Hill, Australia
  • Ep0093 857
    Clayton, Australia
  • Ep0093 850
    Fitzroy, Australia
  • Ep0093 853
    Heidelberg, Australia
  • Ep0093 859
    Herston, Australia
  • Ep0093 852
    Melbourne, Australia
  • Ep0093 856
    Randwick, Australia
  • Ep0093 854
    Westmead, Australia
  • Ep0093 102
    Brugge, Belgium
  • Ep0093 101
    Brussels, Belgium
  • Ep0093 105
    Gent, Belgium
  • Ep0093 100
    Leuven, Belgium
  • Ep0093 107
    Ottignies, Belgium
  • Ep0093 075
    Sarajevo, Bosnia and Herzegovina
  • Ep0093 082
    Tuzla, Bosnia and Herzegovina
  • Ep0093 150
    Blagoevgrad, Bulgaria
  • Ep0093 151
    Pleven, Bulgaria
  • Ep0093 153
    Pleven, Bulgaria
  • Ep0093 156
    Pleven, Bulgaria
  • Ep0093 152
    Sofia, Bulgaria
  • Ep0093 154
    Sofia, Bulgaria
  • Ep0093 155
    Sofia, Bulgaria
  • Ep0093 200
    Greenfield Park, Canada
  • Ep0093 205
    London, Canada
  • Ep0093 201
    Montréal, Canada
  • Ep0093 125
    Zagreb, Croatia
  • Ep0093 254
    Brno, Czechia
  • Ep0093 255
    Ostrava, Czechia
  • Ep0093 251
    Praha 6, Czechia
  • Ep0093 250
    Praha, Czechia
  • Ep0093 253
    Praha, Czechia
  • Ep0093 016
    Aarhus, Denmark
  • Ep0093 015
    Odense, Denmark
  • Ep0093 277
    Tallinn, Estonia
  • Ep0093 276
    Tallin, Estonia
  • Ep0093 275
    Tartu, Estonia
  • Ep0093 027
    Tampere, Finland
  • Ep0093 307
    Clermont-Ferrand, France
  • Ep0093 309
    Dijon, France
  • Ep0093 300
    Lille, France
  • Ep0093 302
    Montpellier, France
  • Ep0093 303
    Rennes, France
  • Ep0093 301
    Strasbourg, France
  • Ep0093 365
    Berlin, Germany
  • Ep0093 362
    Bernau, Germany
  • Ep0093 363
    Bielefeld, Germany
  • Ep0093 358
    Bonn, Germany
  • Ep0093 350
    Frankfurt, Germany
  • Ep0093 360
    Freiburg, Germany
  • Ep0093 368
    Jena, Germany
  • Ep0093 366
    Kehl, Germany
  • Ep0093 357
    Leipzig, Germany
  • Ep0093 353
    Marburg, Germany
  • Ep0093 354
    München, Germany
  • Ep0093 351
    Münster, Germany
  • Ep0093 356
    Osnabrück, Germany
  • Ep0093 352
    Tübingen, Germany
  • Ep0093 426
    Thessaloníki, Greece
  • Ep0093 427
    Thessaloníki, Greece
  • Ep0093 400
    Budapest, Hungary
  • Ep0093 403
    Budapest, Hungary
  • Ep0093 402
    Debrecen, Hungary
  • Ep0093 035
    Cork, Ireland
  • Ep0093 462
    Bologna, Italy
  • Ep0093 450
    Cagliari, Italy
  • Ep0093 451
    Foggia, Italy
  • Ep0093 461
    Foggia, Italy
  • Ep0093 452
    Milano, Italy
  • Ep0093 459
    Pavia, Italy
  • Ep0093 458
    Pozzilli, Italy
  • Ep0093 455
    Roma, Italy
  • Ep0093 457
    Roma, Italy
  • Ep0093 460
    Roma, Italy
  • Ep0093 526
    Asahikawa, Japan
  • Ep0093 501
    Asaka, Japan

Showing the first 100 of 156 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Dec 2020, 27 months.

Results were first posted in Dec 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2017
First posted
Dec 12, 2017
StartActual
Aug 27, 2018
Primary completionActual
Dec 11, 2020
CompletionActual
Dec 11, 2020
Results first posted
Dec 29, 2021
Last update
Dec 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03370120
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Aug 27, 2018
Primary completion
Dec 11, 2020
Completion
Dec 11, 2020
Results posted
Dec 29, 2021
Last update
Dec 29, 2021

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Padsevonil

Start the discussion